The challenges in health care cannot be resolved overnight, but bringing together experts and influencers is essential to keep the conversation — and solutions — moving in the right direction.
Optum® leaders are often a part of those conversations, and Johns Hopkins Medicine has invited Optum Life Sciences President Curt Medeiros to participate in one of its series. Medeiros will join a select panel of health care executives on Wednesday, September 27, for Johns Hopkins Medicine’s On the Road to Precision Medicine Health Care Leader Series.
Johns Hopkins Medicine started this series with the goal of bringing together thought leaders from all sectors to discuss how to improve the way health care is tailored to individuals, and create better ways to engage people in the health care system. The impacts of cost, communication, research and health care delivery on precision medicine factor into these discussions.
Focusing on “Lower Cost, Better Care,” this month’s event will highlight the effect of rising medical costs, and how health care providers and other stakeholders are working together to find ways to decrease patients’ financial burdens while driving improved outcomes. The event will be held at the Senate Visitors Center on Capitol Hill in Washington, D.C.
In addition to Medeiros, other health care executives participating this panel include:
- Moderator: Paul Rothman— Dean of the Medical Faculty; CEO of Johns Hopkins Medicine
- Michael Kanter— Executive Vice President of Quality and Chief Quality Officer, The Permanente Federation; Medical Director, Quality and Clinical Analysis, Southern California Permanente Medical Group
- Peter Pronovost— Senior VP for Patient Safety and Quality, Johns Hopkins Medicine; Director, Armstrong Institute for Patient Safety and Quality
- Lisa Simpson— President and CEO of AcademyHealth
To learn more about the Johns Hopkins Medicine event series, click here.
About the Author:
Curt Medeiros, President, Optum Life Sciences
Curt has spent the last six years in various leadership roles at Optum and has more than 20 years of pharmaceutical industry and consulting experience, including positions with Merck and Deloitte Consulting. He holds an MBA from Harvard Business School, and a BS in chemical engineering from the Massachusetts Institute of Technology (MIT).